Does Nexletol Lower Triglycerides?
No, Nexletol (bempedoic acid) does not meaningfully lower triglycerides and may actually result in modest increases compared to placebo in some patient populations.
Evidence from FDA-Approved Labeling and Clinical Trials
The FDA label for Nexletol explicitly addresses triglyceride effects. In the pivotal CLEAR Outcomes trial (Trial 1), triglycerides were examined as exploratory endpoints and showed a median percent change from baseline to Week 12 of +3% with bempedoic acid 1. This modest increase contrasts with the drug's robust effects on LDL-C (17-18% reduction) and other atherogenic lipoproteins 2.
Mechanism Explains Lack of Triglyceride Effect
Bempedoic acid works as an ATP-citrate lyase (ACL) inhibitor that specifically targets cholesterol biosynthesis in the liver, not triglyceride metabolism 1. The drug requires activation by very long-chain acyl-CoA synthetase 1 (ACSVL1), which is expressed primarily in hepatocytes, leading to upregulation of LDL receptors and decreased LDL-C 1. This mechanism does not directly impact triglyceride synthesis or clearance pathways.
Nuanced Findings Across Patient Populations
A pooled analysis of four phase 3 studies provides important context 3. In patients without metabolic syndrome, triglycerides actually increased with bempedoic acid, but only to a lesser extent than with placebo (placebo-corrected difference: -4.4%; p = 0.02). However, this represents a relative benefit rather than an absolute reduction. The meta-analysis by Feng et al. confirmed that bempedoic acid did not significantly modify triglyceride levels overall (MD -1.51%; 95% CI -3.75%, 0.74%; p = 0.189) 4.
Clinical Implications
Primary indication: Bempedoic acid is FDA-approved specifically for LDL-C lowering in adults with ASCVD or heterozygous familial hypercholesterolemia as adjunct to maximally tolerated statin therapy 2
Not for hypertriglyceridemia: If your patient requires triglyceride lowering, bempedoic acid is not the appropriate choice. Consider fibrates, omega-3 fatty acids, or icosapent ethyl instead
Lipid panel expectations: When initiating bempedoic acid, counsel patients that they should expect significant LDL-C reductions (17-22%) but no meaningful triglyceride improvement 1, 4
Common Pitfall to Avoid
Do not prescribe bempedoic acid expecting comprehensive lipid panel improvement. The drug's benefits are specific to LDL-C, non-HDL-C, apolipoprotein B, and total cholesterol 1. While it reduces hs-CRP by approximately 27% 4, triglycerides remain essentially unchanged or may slightly increase.